News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
369,518 Results
Type
Article (18089)
Company Profile (116)
Press Release (351313)
Section
Business (118241)
Career Advice (512)
Deals (20555)
Drug Delivery (66)
Drug Development (51422)
Employer Resources (54)
FDA (8590)
Job Trends (8295)
News (201808)
Policy (17683)
Tag
Academia (899)
Alliances (26740)
Alzheimer's disease (714)
Approvals (8570)
Artificial intelligence (87)
Bankruptcy (183)
Best Places to Work (6355)
Breast cancer (80)
Cancer (681)
Cardiovascular disease (56)
Career advice (446)
Cell therapy (113)
Clinical research (42305)
Collaboration (210)
Compensation (94)
COVID-19 (1011)
C-suite (56)
Data (693)
Diabetes (73)
Diagnostics (2438)
Drug pricing (59)
Earnings (52314)
Events (66426)
Executive appointments (189)
FDA (8866)
Funding (168)
Gene therapy (91)
GLP-1 (348)
Government (1926)
Healthcare (7555)
Infectious disease (1042)
Inflammatory bowel disease (67)
Interviews (68)
IPO (9282)
Job creations (2238)
Job search strategy (406)
Layoffs (194)
Legal (4100)
Lung cancer (122)
Manufacturing (108)
Medical device (4302)
Medtech (4304)
Mergers & acquisitions (11332)
Metabolic disorders (211)
Neuroscience (879)
NextGen Class of 2024 (2552)
Non-profit (1379)
Northern California (823)
Obesity (126)
Opinion (121)
Parkinson's disease (50)
Patents (57)
People (33036)
Pharmaceutical (65)
Phase I (11353)
Phase II (18238)
Phase III (15653)
Pipeline (233)
Postmarket research (1812)
Preclinical (4771)
Radiopharmaceuticals (152)
Rare diseases (122)
Real estate (3059)
Regulatory (12342)
Research institute (975)
Resumes & cover letters (66)
Southern California (751)
Startups (1869)
United States (7221)
Vaccines (192)
Weight loss (95)
Date
Today (102)
Last 7 days (669)
Last 30 days (2313)
Last 365 days (20758)
2024 (18540)
2023 (22674)
2022 (29201)
2021 (30376)
2020 (28602)
2019 (22778)
2018 (17607)
2017 (18796)
2016 (17942)
2015 (21501)
2014 (16972)
2013 (13849)
2012 (14917)
2011 (15715)
2010 (14235)
Location
Africa (364)
Arizona (67)
Asia (23988)
Australia (3445)
California (1805)
Canada (780)
China (154)
Colorado (82)
Connecticut (91)
Europe (51393)
Florida (220)
Illinois (166)
Indiana (113)
Kansas (56)
Maryland (269)
Massachusetts (1524)
Michigan (55)
Minnesota (119)
New Jersey (568)
New York (533)
North Carolina (395)
Northern California (823)
Ohio (62)
Pennsylvania (442)
South America (583)
Southern California (751)
Texas (240)
Virginia (52)
Washington State (194)
369,518 Results for "purdue pharmaceuticals l p".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Purdue Pharma L.P. Awards Grant for Investigator-initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection
Purdue Pharma L.P. (“Purdue”) announced today that the Company has awarded an investigator-initiated research (IIR) grant to a team of researchers at The University of New Mexico (UNM) for the evaluation of nalmefene hydrochloride (HCl) injection 2mg/2mL (1mg/1mL) in the emergency department setting.
March 27, 2024
·
7 min read
Pharm Country
FDA Accepts Filing of New Drug Application for Nalmefene Auto-injector for the Treatment of Known or Suspected Opioid Overdose
Purdue Pharma L.P. (“Purdue”) announced today that FDA has accepted for filing the company’s New Drug Application (NDA) for the auto-injector delivery form of nalmefene hydrochloride injection*.
April 8, 2024
·
6 min read
Business
Alkeus Pharmaceuticals Appoints Eric L. Trachtenberg as Chief Legal Officer
Alkeus Pharmaceuticals, Inc. today announced that Eric L. Trachtenberg, J.D., M.B.A., has joined the company as Chief Legal Officer.
May 29, 2024
·
2 min read
Pharm Country
Purdue Pharma L.P. to Provide Funding Opportunities for Investigator-Initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection
Purdue Pharma L.P. is accepting proposals for investigator-initiated research (IIR) to examine the outcomes associated with the use of Nalmefene Hydrochloride injection, 2mg/2mL (1mg/1mL).
March 28, 2023
·
6 min read
Business
Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer
Daxor Corporation today announces the appointment of Dr. John L. Jefferies, M.D., M.B.A., M.P.H., F.A.C.C., F.A.H.A., F.A.A.P., F.H.F.S.A., F.E.S.C., F.R.C.P.E., as Chief Medical Officer.
June 5, 2024
·
4 min read
Ono Expands Investment in Ono Venture Investment Fund I, L.P. to US$200 Million
Ono Pharmaceutical Co., Ltd. announced that in order to accelerate the open innovation, it has increased its investment pool from US$100 million to US$200 million to continue strategic investment in Ono Venture Investment Fund I, L.P., which was established as a corporate venture capital fund in CA, USA in May 2020.
December 1, 2023
·
1 min read
Business
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
KalVista Pharmaceuticals, Inc. announced that Benjamin L. Palleiko, the Company’s current President, CBO and CFO, has been appointed as Chief Executive Officer and a director of the Company, effective immediately.
March 7, 2024
·
4 min read
Policy
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. have entered into a binding settlement agreement and mutual release settling ongoing litigation.
December 1, 2023
·
6 min read
Stomach cancer
FDA Sets Adcomm Meeting to Assess Checkpoint Inhibitors in Stomach Cancer Using PD-L1
The Oncologic Drugs Advisory Committee in a Sept. 26 meeting will discuss whether the regulator should restrict approval of checkpoint inhibitors based on PD-L1 expression levels.
August 23, 2024
·
2 min read
·
Tristan Manalac
Pharm Country
Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
Tonix Pharmaceuticals Holding Corp. announced today that Seth Lederman, M.D., Chief Executive Officer, will participate virtually in a fireside chat at A.G.P.’s Healthcare Company Showcase on Tuesday, May 21, 2024, at 9:00 a.m. ET.
May 15, 2024
·
3 min read
1 of 36,952
Next
